Molecular Partners Rethinks Tetra-Specific Dosing After Seeing ‘Suboptimal Exposure’ in Cancer Trial

Molecular Partners has identified “suboptimal exposure” to its tetra-specific T cell engager as the potential cause of the limited response rate in its early-phase trial, prompting the Swiss biotech to change the protocol to try to dial up the impact of the compound.